nuclear medicine michael r. lewis, ph.d. associate professor department of veterinary medicine &...
TRANSCRIPT
![Page 1: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/1.jpg)
Nuclear Medicine
Michael R. Lewis, Ph.D.Associate Professor
Department of Veterinary Medicine & Surgery
Department of Radiology
Nuclear Science & Engineering Institute
![Page 2: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/2.jpg)
Fisson/Reactor Products Cyclotron Products
• Generally decay by - emission because of excess neutrons
• Not many are useful for diagnostic imaging, but several are useful for radiotherapy
• Generally decay by + emission or electron capture because of excess protons
• Many are useful for diagnostic imaging
(gamma scintigraphy or positron emission tomography)
![Page 3: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/3.jpg)
Definition of Radiopharmaceutical
• Radioactive compound used for diagnosis and/or therapy of diseases
• In nuclear medicine, ~95% of radiopharmaceuticals used for diagnosis, while the rest are used for therapy
• Radiopharmaceuticals have no pharmacologic effect, since they are used in tracer quantities
![Page 4: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/4.jpg)
Ideal Radiopharmaceutical for Imaging -Factors to Consider
• Administering to patients– What is the radiation dose to normal organs?– Radiochemical and radionuclidic purity must
be extremely high– Regulatory approval required for human use
• Scope and limitations of instrumentation– Gamma scintigraphy vs. single photon
emission computed tomography (SPECT) vs. positron emission tomography (PET)
![Page 5: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/5.jpg)
Ideal Physical Characteristics of Imaging Radiopharmaceutical
• Decay Mode– gamma (gamma scintigraphy) or positron (PET) and - emitters avoided if at all possible; cause
higher absorbed dose to organs and tissues
• “Good” Energy emissions of radionuclide– Easily collimated and shielded (lower dose to
personnel)– easily detected using NaI crystals (e.g. Tc-99m
decays by 140 keV photons which is ideal)– low radiation dose to the patient (no or )
![Page 6: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/6.jpg)
Ideal Physical Characteristics of Imaging Radiopharmaceutical
• Ideal half-life– long enough to formulate RaPh and accomplish
imaging study– short enough to reduce overall radiation dose to
the patient– physical half-life of radionuclide should be
matched well to biological half-life of RaPh
• Readily Available– geographic distance between user and supplier
limits availability of short-lived radionuclides/RaPh– Generator-produced radionuclides are desirable
![Page 7: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/7.jpg)
Ideal Biological Characteristics of Radiopharmaceutical
• Ideal biological half-life– long enough to complete the procedure
(i.e. localize to target tissue while minimizing background)
– short enough to reduce overall radiation dose to the patient
• High target:non-target ratio– rapid blood clearance– rapid localization in target tissue– rapid clearance from non-target tissues (liver,
kidney, intestines)
![Page 8: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/8.jpg)
Radioactive Decay Processes
1. alpha ++
2. beta minus -
3. beta plus + 4. e- capture EC 5. isomeric transition 6. Internal conversion IC
![Page 9: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/9.jpg)
Diagnostic Nuclear Medicine
![Page 10: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/10.jpg)
![Page 11: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/11.jpg)
Anatomic vs. Physiologic Imaging
![Page 12: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/12.jpg)
How does Physiologic Imaging Work?
Anatomy vs. Function in a broken leg
![Page 13: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/13.jpg)
Anatomy vs. Physiology
![Page 14: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/14.jpg)
Gamma Camera
• device most commonly used to obtain an image in nuclear medicine
• sometimes called a scintillation camera or Anger camera
• camera obtains an image of the distribution of a RaPh in the body (or organ) by detection of emitted -rays
![Page 15: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/15.jpg)
Gamma Camera Consists of…
• A collimator• sodium iodide crystal (detector)• photomultiplier (PM) tube array• position circuit• summation circuit• pulse height analyzer
![Page 16: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/16.jpg)
Sodium Iodide Detector
• Gamma rays which interact in the crystal will deposit energy in the crystal to produce “fast electrons” with high kinetic energy
• Mechanisms of interaction are:– Photoelectric effect– Compton scatter– Pair production (not relevant to NM)
![Page 17: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/17.jpg)
Sodium Iodide Detector, cont’d...
• As electrons slow down in crystal their KE is converted, in part, into light scintillations
• A relatively constant proportion of the light scintillations (produced by each -ray) will exit the crystal and hit the photocathode of the photomultiplier tube
• The crystals used in gamma cameras are typically 40-60 cm in diameter and 1 cm thick
![Page 18: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/18.jpg)
Collimator
• The purpose of the collimator is to define a field of view
• each very small area of the detector ‘sees’ only a small part of the organ to be imaged
• two basic types of collimators:– multi-hole (4000-10000 holes) (used more in
modern gamma cameras)– single or pin-hole
![Page 19: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/19.jpg)
![Page 20: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/20.jpg)
Gamma Camera Basics*
*JPNM Physics website
![Page 21: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/21.jpg)
GE Whole Body Gamma Camera
![Page 22: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/22.jpg)
SPECT Imaging
![Page 23: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/23.jpg)
Mo-99/Tc-99m GeneratorColumn Chromatography
When saline is passedover column, the 99mTcO4
-
is dissolved and lessstrongly adsorbed to alumina.
![Page 24: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/24.jpg)
Cardiac Infarction
201TlCl Rest99mTc-Sestamibi
Stress Test
![Page 25: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/25.jpg)
Cardiac Ischemia
201TlCl Rest99mTc-Sestamibi
Stress Test
![Page 26: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/26.jpg)
O
PHO O
OH
P
O
OH
OH
O
PHOH2C
OH
P
O
OH
OH
C
CH3
Pyrophosphate
OH
C
Methylenediphosphonate
H
OH
Hydroxyethylenediphosphonate
Hydroxymethylenediphosphonate
Inorganic Phosphate Organic Phosphates
(MDP)
(EDP)
(HDP)
![Page 27: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/27.jpg)
Normal Canine Bone Scan
• 99mTc-MDP (Methylene Diphosphonate)
![Page 28: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/28.jpg)
Rib Metastasis
![Page 29: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/29.jpg)
11-year old boy with a one month history of right kneepain
Increase activity in the righttibia
Diagnosis: Osteosarcoma
Juvenile Osteosarcoma
![Page 30: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/30.jpg)
Metastatic Prostate Carcinoma
Imaging
99mTc-HDP
![Page 31: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/31.jpg)
Principle of PET Imaging
Each annihilation produces two 511 keV photons traveling in opposite directions (180O) which are detected by the detectors surrounding the subject
![Page 32: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/32.jpg)
GLUT
PLASMA TISSUE
FDG
Fluorodeoxyglucose MetabolismFluorodeoxyglucose Metabolism
12
O
18F
HOHO
OH
OH12
O
18F
HOHO
OH
OH
12
O
18F
HOHO
OH
HKO P
![Page 33: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/33.jpg)
[18F]Fluorodeoxyglucose (FDG)
![Page 34: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/34.jpg)
PET
Control Alzheimer’s Disease
Center for Functional Imaging; Life Sciences Division; Lawrence Berkeley National Laboratory; Berkeley, CA.
Brain Metabolism ([18F]FDG)
![Page 35: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/35.jpg)
[11C]Raclopride PET Brain Study
Normal
Cocaine Abuser
Courtesy BNL PET Project
nCi/cc1000
800
600
400
200
0
![Page 36: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/36.jpg)
Therapeutic Nuclear Medicine
![Page 37: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/37.jpg)
![Page 38: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/38.jpg)
Fission products useful in nuclear medicine include:99Mo, 131I, 133Xe, 137Cs and 90Sr
Mo-99 I-131
![Page 39: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/39.jpg)
DifferentiatedThyroid
Carcinoma
5 mCi Na131I
ImagingTreatment Planning
48 h p.i.
![Page 40: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/40.jpg)
DifferentiatedThyroid
Carcinoma
Therapy
105 mCi Na131I
27 h p.i.
![Page 41: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/41.jpg)
Differentiated Thyroid CarcinomaPost Surgical Resection
Therapy57Co Flood Source + 105 mCi Na131I
![Page 42: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/42.jpg)
Differentiated Thyroid Carcinoma
201TlCl and 99mTc-Sestamibi Imaging
4 months after Na131I Therapy
![Page 43: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/43.jpg)
Canine OsteosarcomaTumor distal radius
![Page 44: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/44.jpg)
Story of QuadraMetTM -- I
• 153Sm identified as a useful nuclide for radiotherapy by MU researchers
• Development began in early 1980’s at MU in collaboration with the Dow Chemical Company [phosphonate ligand complexes;153Sm-EDTMP]
• Successful in treatment of primary osteosarcoma in canine patients, with added bonus of 18% cure rate [MU College of Veterinary Medicine]
![Page 45: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/45.jpg)
One of Our First Patients
![Page 46: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/46.jpg)
Bone Scans of Canine Patient
Before Treatment: 8/15/85 After Treatment: 3/3/86
![Page 47: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/47.jpg)
Results of Clinical Trial of153Sm-EDTMP in Canine Osteosarcoma
Response # of Dogs (%) Survival (months)
Disease Free 7 (18%) 11 - 60
Partial Response 25 (62%) 1 - 16
No Response 8 (20%) 0.5 - 1
![Page 48: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/48.jpg)
Story of QuadraMet™ -- II
• Clinical trials began in late 1980’s, with doses supplied by MURR for Phase I studies
• ~80% efficacy, with ~25% obtaining full pain remission
• Approved in U.S. for pain palliation of metastatic bone cancer in March, 1997
![Page 49: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/49.jpg)
153Sm-EDTMP [QuadraMet]99m99mTc-MDPTc-MDP 153153Sm-EDTMPSm-EDTMP
NN
PO3H2
PO3H2
PO3H2
PO3H2
153153SmSm
+
![Page 50: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/50.jpg)
Experimental Nuclear Medicine
![Page 51: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/51.jpg)
1. Targeting vector (e.g., mAb, peptide hormone, small molecule, etc.)
2. Radionuclide (e.g., diagnostic – 99mTc, 111In, etc.; therapeutic – 188Re, 90Y, 177Lu, etc.)
3. Bifunctional chelating agent (BCA)4. Linker or spacer
The design of an effective tumor-targeting radio-pharmaceutical involves appropriate selection of:
Radiopharmaceutical Design
TargetingVector
LinkerBifunctional
Chelating Agent
MRadiometal
![Page 52: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/52.jpg)
Hypothesis 1
Non-invasive imaging of bcl-2 mRNA expression in lymphoma may aid in the identification of chemotherapy patient risk groups, who might respond better to targeted immunotherapy, radioimmunotherapy, or antisense therapy.
![Page 53: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/53.jpg)
Receptor Targeting for Molecular Imaging and Therapy
• Radiometal chelation should be stable under physiological conditions.
• Chelate modification should not lower the receptor binding affinity.
![Page 54: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/54.jpg)
Internalizing vs. Non-internalizingReceptors
Bryan JN, et al. Vet. Comp. Oncol. 2004; 2:82-90 Courtesy of Derek B. Fox, D.V.M., Ph.D.
![Page 55: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/55.jpg)
Peptide Nucleic Acid
O
O
B
O P O
O
O-
O
B
O P O
O
O-
O
B
O
N
O
HN
NH
O
B
N
O
NH
O
B
N
O
HN
O
B
DNA
PNA
![Page 56: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/56.jpg)
Cellular Delivery of PNA
Chelator PNA Peptide
![Page 57: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/57.jpg)
DOTA-Tyr3-Octreotate
*M = 111In for gamma scintigraphy and single photon emission tomography (SPECT), 64Cu for positron emission tomography (PET), or 177Lu for targeted radiotherapy (TRT).
N
ONH
D Phe Cys Tyr D Trp
LysThrCysThr
N
N N
COOH COOH
COOH
SS
*M HOOC
![Page 58: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/58.jpg)
PNA and Peptide Conjugates
NN
N NCOOH
HOOC
HOOC
O
NH CCAGCGTGCGCCAT-dPhe-Cys-Tyr-dTrp-Lys-Thr-Cys-Thr(OH)
S S
R1
R2
DOTA-anti-bcl-2-PNA-Tyr3-octreotate
DOTA-Nonsense PNA-Tyr3-octreotateR1= TTGCGACCCTCTTG-dPhe
R2= Cys-Ala-Ala-Ala-Ala-Cys-Thr(OH) DOTA-anti-bcl-2-PNA-Ala
S S
R1= dPhe DOTA-Tyr3-octreotate
![Page 59: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/59.jpg)
MicroSPECT/CT Using 111In-labeledPNA and Peptide Conjugates
(1 h, 48 h)
Antisense
Nonsense
Ala
TATE
Jia F, et al. J. Nucl. Med. 2008; 49: 430-438
![Page 60: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/60.jpg)
Bcl-2 mRNA Expression Levelsin Mec-1 and Ramos Cells
Mec-1 Ramos0
5
102000
2500
3000
3500
4000
Bcl
-2 m
RN
A c
opy
num
ber
rati
o3821
1
(Bcl-2 +) (Bcl-2 -)
![Page 61: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/61.jpg)
MicroSPECT/CT Using111In-DOTA-anti-bcl-2-PNA-Tyr3-octreotate
(48 h)
Mec-1 Ramos
![Page 62: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/62.jpg)
MicroPET/CT Using64Cu-DOTA-anti-bcl-2-PNA-Tyr3-octreotate
Mec-1
Ramos
1 h 3 h 24 h 48 h
![Page 63: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/63.jpg)
Hypothesis 2
Dogs with naturally occurring B-cell
lymphoma will demonstrate tumor
specific uptake of 111In-anti-bcl-2-PNA-
Tyr3-octreotate that correlates
negatively with response to
chemotherapy.
![Page 64: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/64.jpg)
111In-DOTA-Tyr3-OctreotateScintigraphy
Nodes
1 h post-injection 4 h post-injection 24 h post-injection
![Page 65: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/65.jpg)
PNA Imaging of Normal Dog
![Page 66: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/66.jpg)
Partial Remission
Initial Scan
Remission Scan
![Page 67: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/67.jpg)
Complete Remission
Initial Scan
Remission Scan
Relapse Scan
![Page 68: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/68.jpg)
Hypothesis 3
Combined radionuclide and antisense therapy may act synergistically or additively with respect to cell proliferation and viability in an in vitro model of B-cell lymphoma.
![Page 69: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/69.jpg)
Western Blot Analysis
Tubulin
bcl-2
1 2 3 4 5
1. Cells without treatment2. Cells treated with 2 μg of DOTA-anti-bcl-2-PNA-Tyr3-octreotate for 48 h3. Cells without treatment4. Cells treated with 2 μg of DOTA-nonsense-PNA-Tyr3-octreotate for 48h 5. Cells treated with 2 μg of DOTA-anti-bcl-2-PNA-Ala for 48 h
![Page 70: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/70.jpg)
Cell Viability Assay
Day 2 p<0.002
Day 3 p<0.005
177-Lu Labeled PNA Peptide Conjugate
0 1 2 3
60
70
80
90
100
2 g Cold PNA Control2 Gy/ 2g2 Gy/ 5g2 Gy/ 10g
Day
![Page 71: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/71.jpg)
TUNEL Assays
Anti-bcl-2 + Anti-FLIP Anti-bcl-2 + CH11 Anti-bcl-2 Anti-FLIP + CH11
Anti-bcl-2 + Anti-FLIP Anti-bcl-2 + CH11 Anti-bcl-2 Anti-FLIP + CH11SH-SY5Y
IMR-32
![Page 72: Nuclear Medicine Michael R. Lewis, Ph.D. Associate Professor Department of Veterinary Medicine & Surgery Department of Radiology Nuclear Science & Engineering](https://reader035.vdocument.in/reader035/viewer/2022062511/5516c5cd550346f0208b5ab8/html5/thumbnails/72.jpg)
AcknowledgmentsAcknowledgments
Dr. Carolyn Anderson Washington University
Dr. Henry VanBrocklin Lawrence Berkeley Lab
Dr. Joanna Fowler Brookhaven National Lab
Dr. Gregory Daniel University of Tennessee
Dr. Alan Ketring University of Missouri
Dr. Wynn Volkert University of Missouri